Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2750

1.

Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial.

Spackman E, Sculpher M, Howard J, Malfroy M, Llewelyn C, Choo L, Hodge R, Johnson T, Rees DC, Fijnvandraat K, Kirby-Allen M, Davies S, Williamson L.

Eur J Haematol. 2014 Mar;92(3):249-55. doi: 10.1111/ejh.12232. Epub 2013 Dec 12.

2.

Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide.

Caers J, Hafraoui K, Keutgens A, Caberg JH, Lambert F, Tassin F, Beguin Y.

Eur J Haematol. 2014 Feb;92(2):179-80. doi: 10.1111/ejh.12233. Epub 2013 Dec 2. No abstract available.

3.

Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.

Watanabe R, Tomita N, Itabashi M, Ishibashi D, Yamamoto E, Koyama S, Miyashita K, Takahashi H, Nakajima Y, Hattori Y, Motohashi K, Takasaki H, Ohshima R, Hashimoto C, Yamazaki E, Fujimaki K, Sakai R, Fujisawa S, Motomura S, Ishigatsubo Y.

Eur J Haematol. 2014 Mar;92(3):204-10. doi: 10.1111/ejh.12221. Epub 2013 Nov 28.

PMID:
24283206
4.

OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.

Koren-Michowitz M, Buzaglo Z, Ribakovsky E, Schwarz M, Pessach I, Shimoni A, Beider K, Amariglio N, le Coutre P, Nagler A.

Eur J Haematol. 2014 Apr;92(4):283-8. doi: 10.1111/ejh.12235. Epub 2013 Dec 18.

PMID:
24215657
5.

Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.

Masuzawa A, Kiyotani C, Osumi T, Shioda Y, Iijima K, Tomita O, Nakabayashi K, Oboki K, Yasuda K, Sakamoto H, Ichikawa H, Hata K, Yoshida T, Matsumoto K, Kiyokawa N, Mori T.

Eur J Haematol. 2014 Mar;92(3):263-7. doi: 10.1111/ejh.12234. Epub 2013 Nov 28.

PMID:
24215620
6.

Antitumor effects of bevacizumab in a microenvironment-dependent human adult T-cell leukemia/lymphoma mouse model.

Mori F, Ishida T, Ito A, Sato F, Masaki A, Narita T, Suzuki S, Yamada T, Takino H, Ri M, Kusumoto S, Komatsu H, Hishizawa M, Imada K, Takaori-Kondo A, Niimi A, Ueda R, Inagaki H, Iida S.

Eur J Haematol. 2014 Mar;92(3):219-28. doi: 10.1111/ejh.12231. Epub 2013 Nov 26.

PMID:
24188416
7.

Comparison of serial serum ferritin measurements and liver iron concentration assessed by MRI in adult transfused patients with sickle cell disease.

Tsitsikas DA, Nzouakou R, Ameen V, Sirigireddy B, Amos RJ.

Eur J Haematol. 2014 Feb;92(2):164-7. doi: 10.1111/ejh.12230. Epub 2013 Nov 26.

PMID:
24175986
8.

Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.

Krönig H, Kremmler L, Haller B, Englert C, Peschel C, Andreesen R, Blank CU.

Eur J Haematol. 2014 Mar;92(3):195-203. doi: 10.1111/ejh.12228. Epub 2013 Nov 26.

PMID:
24175978
9.

Angiogenesis is increased in advanced haemophilic joint disease and characterised by normal pericyte coverage.

Zetterberg E, Palmblad J, Wallensten R, Morfini M, Melchiorre D, Holmström M.

Eur J Haematol. 2014 Mar;92(3):256-62. doi: 10.1111/ejh.12227. Epub 2013 Nov 25.

PMID:
24168433
10.

Genetic variation in CD36, HBA, NOS3 and VCAM1 is associated with chronic haemolysis level in sickle cell anaemia: a longitudinal study.

Coelho A, Dias A, Morais A, Nunes B, Ferreira E, Picanço I, Faustino P, Lavinha J.

Eur J Haematol. 2014 Mar;92(3):237-43. doi: 10.1111/ejh.12226. Epub 2013 Nov 28.

PMID:
24168396
11.

Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms.

Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, Ayuk F, Wolschke C, Schnittger S, Kohlmann A, Haferlach T, Kröger N.

Eur J Haematol. 2014 Mar;92(3):189-94. doi: 10.1111/ejh.12223. Epub 2013 Nov 21.

PMID:
24164563
12.

Pulmonary involvement in patients with thrombotic thrombocytopenic purpura.

Nokes T, George JN, Vesely SK, Awab A.

Eur J Haematol. 2014 Feb;92(2):156-63. doi: 10.1111/ejh.12222. Epub 2013 Nov 26. Review.

PMID:
24164539
13.

Influence of C-reactive protein levels and age on the value of D-dimer in diagnosing pulmonary embolism.

Crop MJ, Siemes C, Berendes P, van der Straaten F, Willemsen S, Levin MD.

Eur J Haematol. 2014 Feb;92(2):147-55. doi: 10.1111/ejh.12218. Epub 2013 Nov 22.

PMID:
24164492
14.

Salvage therapy of refractory severe aplastic anemia by decreasing cyclosporine dose regimen.

Bertrand A, Philippe M, Bertrand Y, Plantaz D, Bleyzac N.

Eur J Haematol. 2014 Feb;92(2):172-6. doi: 10.1111/ejh.12220. Epub 2013 Dec 2.

PMID:
24147892
15.

Oncogenic ERBB3 mutations altering p.Val104 is rare in acute leukemias and non-Hodgkin lymphomas.

Choi MR, Yoo NJ, Lee SH.

Eur J Haematol. 2014 Feb;92(2):177-8. doi: 10.1111/ejh.12219. Epub 2013 Nov 26. No abstract available.

PMID:
24138610
16.

Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.

Hemmati PG, Schulze-Luckow A, Terwey TH, le Coutre P, Vuong LG, Dörken B, Arnold R.

Eur J Haematol. 2014 Feb;92(2):102-10. doi: 10.1111/ejh.12216. Epub 2013 Nov 21.

PMID:
24138573
17.

Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance.

Wawrzyniak E, Kotkowska A, Blonski JZ, Siemieniuk-Rys M, Ziolkowska E, Giannopoulos K, Robak T, Korycka-Wolowiec A.

Eur J Haematol. 2014 Feb;92(2):91-101. doi: 10.1111/ejh.12215. Epub 2013 Dec 2.

PMID:
24138550
18.

Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients.

Hiramoto N, Kurosawa S, Tajima K, Okinaka K, Tada K, Kobayashi Y, Shinohara A, Inoue Y, Ueda R, Tanaka T, Kim SW, Yamashita T, Heike Y, Fukuda T.

Eur J Haematol. 2014 Feb;92(2):137-46. doi: 10.1111/ejh.12214. Epub 2013 Nov 9.

PMID:
24127668
19.

Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.

Lund J, Uttervall K, Liwing J, Gahrton G, Alici E, Aschan J, Holmberg E, Nahi H.

Eur J Haematol. 2014 Jan;92(1):19-25. doi: 10.1111/ejh.12213. Epub 2013 Nov 15.

PMID:
24118547
20.

MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations.

Pedersen MØ, Gang AO, Poulsen TS, Knudsen H, Lauritzen AF, Nielsen SL, Klausen TW, Nørgaard P.

Eur J Haematol. 2014 Jan;92(1):42-8. doi: 10.1111/ejh.12212. Epub 2013 Nov 11.

PMID:
24118498

Supplemental Content

Loading ...
Support Center